Elizabeth M Poole1, Eva Schernhammer2,3, Leigha Mills4, Susan E Hankinson2,3,5, Shelley S Tworoger2,3. 1. Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Ave, 3rd Floor, Boston, MA, 02115, USA. nhlip@channing.harvard.edu. 2. Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Ave, 3rd Floor, Boston, MA, 02115, USA. 3. Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA. 4. Dana Farber Cancer Institute, Boston, MA, USA. 5. Division of Biostatistics and Epidemiology, School of Public Health and Health Sciences, University of Massachusetts, 715 North Pleasant Street, Amherst, MA, USA.
Abstract
PURPOSE: Melatonin has anti-carcinogenic properties, including modulation of estradiol production, cell cycle regulation, and promotion of apoptosis. Urinary melatonin has been inversely associated with breast cancer in some studies, but the association with ovarian cancer has not been investigated. METHODS: We measured urinary 6-sulfatoxymelatonin (aMT6s) in nested ovarian cancer case-control studies in the Nurses' Health Study (NHS; n = 100 cases; 199 controls) and NHSII (n = 52 cases; 105 controls); samples were mainly from first morning voids. Controls were matched to cases on year of birth, menopause status, use of menopausal hormone therapy, and urine collection characteristics. We evaluated the association of tertiles of aMT6s, corrected for creatinine concentrations, with risk of ovarian cancer using conditional logistic regression. Models were adjusted for key ovarian cancer risk factors, and we additionally evaluated adjustment for usual sleep duration, snoring, and history of rotating night shift work. RESULTS: aMT6s was not significantly associated with risk of ovarian cancer. In multivariable models, the odds ratio comparing the highest tertile of aMT6s to the lowest was 0.79, 95 % confidence interval (CI) 0.40-1.56 in the NHS and 2.88, and 95 % CI in the NHSII 0.97-8.52. Additional adjustment for sleep habits and night shift work had little impact on the observed results. We observed no clear association between urinary melatonin and ovarian cancer risk. CONCLUSIONS: These results are consistent with our previous study in which we reported no association between night shift work and ovarian cancer; however, given the small sample size in our study, additional evaluation in larger studies is warranted.
PURPOSE:Melatonin has anti-carcinogenic properties, including modulation of estradiol production, cell cycle regulation, and promotion of apoptosis. Urinary melatonin has been inversely associated with breast cancer in some studies, but the association with ovarian cancer has not been investigated. METHODS: We measured urinary 6-sulfatoxymelatonin (aMT6s) in nested ovarian cancer case-control studies in the Nurses' Health Study (NHS; n = 100 cases; 199 controls) and NHSII (n = 52 cases; 105 controls); samples were mainly from first morning voids. Controls were matched to cases on year of birth, menopause status, use of menopausal hormone therapy, and urine collection characteristics. We evaluated the association of tertiles of aMT6s, corrected for creatinine concentrations, with risk of ovarian cancer using conditional logistic regression. Models were adjusted for key ovarian cancer risk factors, and we additionally evaluated adjustment for usual sleep duration, snoring, and history of rotating night shift work. RESULTS: aMT6s was not significantly associated with risk of ovarian cancer. In multivariable models, the odds ratio comparing the highest tertile of aMT6s to the lowest was 0.79, 95 % confidence interval (CI) 0.40-1.56 in the NHS and 2.88, and 95 % CI in the NHSII 0.97-8.52. Additional adjustment for sleep habits and night shift work had little impact on the observed results. We observed no clear association between urinary melatonin and ovarian cancer risk. CONCLUSIONS: These results are consistent with our previous study in which we reported no association between night shift work and ovarian cancer; however, given the small sample size in our study, additional evaluation in larger studies is warranted.
Entities:
Keywords:
Circadian rhythm; Melatonin; Ovarian cancer
Authors: Venkatramanujam Srinivasan; Seithikurippu R Pandi-Perumal; Amnon Brzezinski; Kunwar P Bhatnagar; Daniel P Cardinali Journal: Recent Pat Endocr Metab Immune Drug Discov Date: 2011-05
Authors: B C Voordouw; R Euser; R E Verdonk; B T Alberda; F H de Jong; A C Drogendijk; B C Fauser; M Cohen Journal: J Clin Endocrinol Metab Date: 1992-01 Impact factor: 5.958
Authors: Susan B Brown; Susan E Hankinson; A Heather Eliassen; Katherine W Reeves; Jing Qian; Kathleen F Arcaro; Lani R Wegrzyn; Walter C Willett; Eva S Schernhammer Journal: Am J Epidemiol Date: 2015-01-13 Impact factor: 4.897
Authors: Beatriz del Río; Juana M García Pedrero; Carlos Martínez-Campa; Pedro Zuazua; Pedro S Lazo; Sofía Ramos Journal: J Biol Chem Date: 2004-06-30 Impact factor: 5.157
Authors: Eva S Schernhammer; Bernard Rosner; Walter C Willett; Francine Laden; Graham A Colditz; Susan E Hankinson Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-06 Impact factor: 4.254
Authors: C D Bondi; C Alonso-Gonzalez; W P Clafshenkel; M P Kotlarczyk; B R Dodda; E Sanchez-Barcelo; V L Davis; P A Witt-Enderby Journal: Eur J Obstet Gynecol Reprod Biol Date: 2013-12-09 Impact factor: 2.435
Authors: Andrea Polo; Sakshi Singh; Anna Crispo; Marilina Russo; Aldo Giudice; Maurizio Montella; Giovanni Colonna; Susan Costantini Journal: Oncol Lett Date: 2017-09-29 Impact factor: 2.967
Authors: Xuehong Zhang; Megan Rice; Shelley S Tworoger; Bernard A Rosner; A Heather Eliassen; Rulla M Tamimi; Amit D Joshi; Sara Lindstrom; Jing Qian; Graham A Colditz; Walter C Willett; Peter Kraft; Susan E Hankinson Journal: PLoS Med Date: 2018-09-04 Impact factor: 11.069